598 related articles for article (PubMed ID: 10618600)
21. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
22. Risedronate.
Goa KL; Balfour JA
Drugs Aging; 1998 Jul; 13(1):83-91; discussion 92. PubMed ID: 9679211
[TBL] [Abstract][Full Text] [Related]
23. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
24. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Bloomfield DJ
J Clin Oncol; 1998 Mar; 16(3):1218-25. PubMed ID: 9508210
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
26. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
29. [Osteolytic metastases of breast cancer and biphosphonates].
Lortholary A; Alleaume C; Pein F; Larra F
Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
[TBL] [Abstract][Full Text] [Related]
30. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Ralston SH; Gallacher SJ; Patel U; Dryburgh FJ; Fraser WD; Cowan RA; Boyle IT
Lancet; 1989 Nov; 2(8673):1180-2. PubMed ID: 2572902
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
Body JJ
Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
[TBL] [Abstract][Full Text] [Related]
33. The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Harvey HA; Lipton A
Support Care Cancer; 1996 May; 4(3):213-7. PubMed ID: 8739655
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates: biological response modifiers in breast cancer.
Paterson AH
Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
38. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Drake WM; Kendler DL; Brown JP
Clin Ther; 2001 Apr; 23(4):620-6. PubMed ID: 11354395
[TBL] [Abstract][Full Text] [Related]
39. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
[TBL] [Abstract][Full Text] [Related]
40. Treatment of osteoporosis with bisphosphonates.
Watts NB
Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
